UBX Insider Trading
Insider Ownership Percentage: 5.80%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $8,040.02
Unity Biotechnology Insider Trading History Chart
This chart shows the insider buying and selling history at Unity Biotechnology by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Unity Biotechnology Share Price & Price History
Current Price: $0.99
Price Change: ▲ Price Increase of +0.0298 (3.10%)
As of 04/11/2025 05:00 PM ET
Unity Biotechnology Insider Trading History
Unity Biotechnology Institutional Trading History
Data available starting January 2016
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Read More on Unity Biotechnology
Volume
59,072 shs
Average Volume
116,971 shs
Market Capitalization
$16.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.3
Who are the company insiders with the largest holdings of Unity Biotechnology?
Who are the major institutional investors of Unity Biotechnology?
Which major investors are buying Unity Biotechnology stock?
Within the previous quarter, UBX stock was acquired by institutional investors including:
- SeaCrest Wealth Management LLC